Food and Drug Administration, Compound and weight loss

The FDA Cracking Down on Compounded Weight Loss Drugs – Here's What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a federal judge has ruled that compounding pharmacies can’t keep making copies of the drug now that it’s no longer in shortage.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.
US FDA to hold off action on weight-loss drug copies pending court ruling
The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of Novo Nordisk's weight-loss drug Wegovy until a federal court delivers its ruling in a lawsuit against the agency.
Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Medications For Weight Loss
Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
New York Post5d
We went blind after using weight-loss drugs like Ozempic and Mounjaro
Recent studies have shown an association between drugs such as Ozempic, Mounjaro and Wegovy — which have become phenomenally popular for weight loss — and an increased risk of NAION.
Weight Loss Isn’t Always Healthy? Study Finds It Can Be Deadly for Some Patients
A study finds that significant weight loss increases the risk for individuals with cardiovascular disease. New research has ...
Employers face pressure to add coverage of Ozempic, other weight-loss drugs
Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
New ‘natural’ GLP-1 booster that can be added to any food for weight loss to hit shelves within the next year
NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...
Popular weight loss drugs bring unexpected heart health benefits—researchers discuss implications
Weight loss drugs like Ozempic deliver more health benefits than expected.
UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...